(BLUE) - Earnings & Price History

BLUE: - 144.73, $7.32B, 5.63 (4.05%)

Sector: Healthcare - Industry: Biotechnology

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its product candidates include Lenti-D, which is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, as well as a phase I study in the United States for the treatment of severe SCD. The companys lead chimeric antigen receptor T cell-based product candidate is bb2121, which is in phase I clinical trials for the treatment of relapsed and refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; an

Past BLUE reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2014-11-13Bluebird Bio-0.52-0.6139.1441.2341.1938.641.6-0.10%-4.98%-5.07%367.00K
2014-08-13Bluebird Bio-0.45-0.0635.1134.9434.934.5535.26-0.11%0.60%0.49%281.80K
2014-06-04Bluebird Bio-0.32-0.4422.5822.3722.3922.1522.710.09%▲0.85%0.94%83.40K
2014-03-06Bluebird Bio-0.3-0.3425.9524.124.2123.2526.210.46%7.19%7.68%385.50K
2013-11-13Bluebird Bio-0.2-0.2620.0220.5919.3719.3721.48-5.93%3.36%-2.77%141.00K

Login | Register
Tuesday Jun 18, 2019   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR


index chart
index color